[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Monaco\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":408},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,38,64,91,122,149,176,203,234,261,292,312,333,358,381],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100289852","rhythmia-mapping-and-signal-acquisition-for-data-analysis-rhapsody-100289852",false,"NCT03053141","RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)","RHAPSODY","Inclusion Criteria:\n\n1. Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law\n2. Scheduled for standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System.\n\nExclusion Criteria:\n\n1. Prothrombotic or bleeding tendency due to coagulopathy or blood dyscrasia\n2. Inability to tolerate heparin therapy (e.g. heparin induced thrombocytopenia, allergy, etc.)\n3. Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or in the path of the catheter access route\n4. Active systemic infection or sepsis\n5. Hemodynamic instability or shock at baseline precluding ablation in the assessment of the investigator.\n6. Presence of intracardiac thrombus, tumor, or other abnormality which precludes catheter introduction\n7. Women who are pregnant or lactating\n8. Cardiac surgery within the past 90 days\n9. Acute myocardial infarction within 3 months\n10. Stable\u002Funstable angina or ongoing myocardial ischemia\n11. Subjects with an active heart failure decompensation\n12. Long QT Syndrome, Brugada Syndrome, or Torsade de Pointes\n13. Congenital heart disease with or without corrective surgery that would complicate a mapping procedure\n14. Subjects having untreatable allergy to contrast media\n15. Vascular pathology or tortuosity precluding standard vascular access techniques\n16. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.",[24],"Cardiac Arrythmias","RECRUITING","2026-07-29",{"date":28,"type":29},"2026-07-31","ACTUAL",{"date":31,"type":29},"2016-05",{"date":33,"type":20},"2027-12",{"name":35,"class":36},"Boston Scientific Corporation","INDUSTRY",8,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100644741","comparison-of-oral-administration-of-a-jak-inhibitor-in-rheumatoid-arthritis-100644741","NCT07674134","Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis","Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis","JAK-INHI","Inclusion Criteria:\n\n* Patient aged over 18 years\n* Patient with Rheumatoid Arthritis according to the 2010 ACR\u002FEULAR criteria\n* Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations\n* Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.\n\nExclusion Criteria:\n\n* No contraindication to a bDMARD\n* Not stable dose of corticosteroids in the 4 weeks preceding enrollment\n* Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment\n* Prior treatment with a JAK inhibitor\n* Patient unable to be followed-up in the study during 6 months\n* Minors or adults under guardianship or curatorship, or deprived of their liberty\n* Pregnant or breastfeeding patient\n* Patient refusing to use an effective method of contraception for the duration of the study\n* Person not affiliated with a social security scheme.",{"count":47,"type":20},90,"The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.\n\nThe objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.",[50],"Rheumatoid Arthritis (RA)",[52],"JAK inhibitor","2026-06-23",{"date":55,"type":29},"2026-06-29",{"date":57,"type":29},"2024-04-23",{"date":59,"type":20},"2026-11",{"name":61,"class":62},"Centre Hospitalier Princesse Grace","OTHER",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":74,"studyType":21,"phases":4,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100441386","the-global-paradise-system-registry-100441386","NCT05027685","The \"Global Paradise System\" Registry","The \"Global Paradise® System\" Registry","GPSRegistry","Inclusion Criteria:\n\n* Appropriately signed and dated informed consent\n* Age ≥18 at time of consent\n* Patient candidate for renal denervation with the Paradise System based on physician's assessment OR Patient treated with the Paradise Ultrasound Renal Denervation System within the 6 months prior to consent\n\nExclusion Criteria:\n\nPatients who meet any of the contraindications listed in the Instructions for Use will be excluded.\n\nThe contraindications are:\n\n* Stented renal artery\n* Less than 18 years of age\n* Pregnant\n* Known allergy to contrast medium\n* Renal arteries diameter \\\u003C 3 mm and \\> 8 mm\n* Renal artery with Fibromuscular (FMD) disease\n* Renal artery aneurysm\n* Renal artery stenosis of any origin \\>30%\n* Iliac\u002Ffemoral artery stenosis precluding insertion of the Paradise catheter",{"count":73,"type":20},3000,"5 Years","The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry. In addition to collecting data from patients treated as per standard clinical practice, the Registry will also regularly collect telemetric Home Blood Pressure (HBP) measurements and Patient Reported Outcome (PRO) data via a standardized quality of life questionnaire. The objective of the GPS Registry is to document the long-term safety and effectiveness of the commercially available Paradise Ultrasound Renal Denervation System when used per its labelling in patients deemed to be candidates for RDN as per physician's assessment.",[77],"Hypertension",[77,79,80],"Blood pressure","Renal Denervation","2026-06-02",{"date":83,"type":29},"2026-06-04",{"date":85,"type":29},"2022-01-13",{"date":87,"type":20},"2031-12-31",{"name":89,"class":36},"ReCor Medical, Inc.",55,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":63},"100639599","pain-assessment-during-rapid-sequence-induction-100639599","NCT07588165","Pain Assessment During Rapid Sequence Induction","Nociception Assessment During Rapid Sequence Induction: A Prospective Observational Study of Practices and Complications - The NARSI Study","NARSI","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Patient requiring tracheal intubation after rapid sequence induction in the visceral surgery operating room\n* Pain monitoring by Analgesia Nociception Index (ANI) as part of general anesthesia\n\nExclusion Criteria:\n\n* Patient with atrial fibrillation at the time of intubation following rapid sequence induction\n* Patient on long-term beta-blocker therapy",{"count":100,"type":20},150,"Rapid sequence induction (RSI) is a standard anesthesia technique used in patients at risk of aspiration. Although tracheal intubation following RSI is a frequent and painful procedure, no study has yet evaluated nociception using the Analgesia Nociception Index (ANI) during this procedure.\n\nThis monocentric prospective observational study aims to describe the impact of RSI on pain measured by ANI, and to explore early complications (desaturation, hypotension, regurgitation) and factors associated with pain and complications. 150 patients undergoing RSI in the visceral surgery operating room at CHPG Monaco will be analyzed.",[103,104,105,106],"Rapide Sequence Induction","Tracheal Intubation","Nociception","General Anesthesia",[108,109,110,111,112,113],"Analgesia Nociception Index (ANI)","Rapid Sequence Induction (RSI)","Pain monitoring","Tracheal intubation","Hemodynamic response","General anesthesia","2026-05-22",{"date":116,"type":29},"2026-05-27",{"date":118,"type":29},"2026-05-21",{"date":120,"type":20},"2028-05",{"name":61,"class":62},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100635892","retro-prospective-postmarket-clinical-study-for-fx-shoulder-solutions-shoulder-systems-100635892","NCT07558590","RETRO-PROSPECTIVE POSTMARKET CLINICAL STUDY FOR FX SHOULDER SOLUTIONS SHOULDER SYSTEMS","Inclusion Criteria:\n\n* Indication for hemi or total shoulder replacement with one of the FX SHOULDER SOLUTIONS Shoulder Systems, according to its IFU and surgical technique.\n* Patient aged 18 years and above\n* Patient insured with a social security system\n* Has been informed and did consent to participate to the study.\n\nExclusion Criteria:\n\n* Neurological pathologies compromising the shoulder stability\n* Morbid obesity\n* Muscular deficiencies impairing the shoulder joint",{"count":129,"type":20},1004,"This study takes place in the framework of the PostMarket Clinical Follow-up plan of the Shoulder Systems commercialized by FX SHOULDER SOLUTIONS.\n\nThe included cases will be followed for 10 years after index surgery. Primary objective is the assessment in real life of the revision rate of the shoulder systems at long-term.\n\nSecondary objectives are\n\n* Revision rate at each post op visit\n* Range of motion at each post op visit\n* Quick Dash, Constant, American Shoulder and Elbow Surgeons Shoulder Score (ASES), Subjective Shoulder Value (SSV), Pain scores at each post op visit\n* Radiological assessment of implant positioning through geometrical parameters at each post op visit\n* Incidence of complications at each post op visit\n* Qualitative feedback from surgeons on the instrumentation",[132,133,134,135,136,137,138],"Humeral Fracture, Proximal","Glenohumeral Osteoarthritis","Avascular Necrosis of the Head of Humerus","Rotator Cuff Tear","Rotator Cuff Arthropathy","Inflammatory Arthritis","Revision of a Shoulder Prosthesis","2026-04-24",{"date":141,"type":29},"2026-04-30",{"date":143,"type":29},"2020-06-01",{"date":145,"type":20},"2037-06",{"name":147,"class":36},"FX Solutions",22,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100321629","phase-1-phase-i-trial-of-carbonic-anhydrase-inhibition-in-combination-with-radiochemotherapy-or-radioimmunotherapy-in-small-cell-lung-carcinoma-100321629","NCT03467360","Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma","ICAR","Inclusion Criteria:\n\n* Age \\> or = 18 years,\n* Performance Status 0 to 2,\n* Patient with an histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer,\n* Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group) or Patient who received 4 cycles of chemoimmunotherapy with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as the first treatment (extensive SCLC sub-group) Note: The decision of the Multidisciplinary Consultation Team must be notified in the patient's medical file,\n* Evaluation lesion according to the criteria RECIST 1.1 and \u002F or according to the criteria PERCIST 1.0,\n* Women of childbearing potential must have a negative serum pregnancy test within 72 hours of the first administration of the study treatment,\n* If the patient is a woman of childbearing potential, she must be surgically sterile or agree to use two adequate methods of contraception throughout the duration of the study until 1 month after the last administration of the study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception,\n* If the male patient has one or more female partners of childbearing age, he \u002F she must agree to use an adequate method of contraception, starting at the first administration of the study treatment up to 1 month after the last administration of the treatment. of the study, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception,\n* Patient willing and able to provide written informed consent\u002Fassent for the trial,\n* Patient affiliated with a health insurance system.\n\nExclusion Criteria:\n\n* Patient with metastatic disease,\n* History of thoracic irradiation or near \u002F in the thoracic irradiation field,\n* Patient who refuses to participate in the study or unable to agree,\n* Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction \\\u003C30%, clinical signs), severe respiratory failure:\n\n  * COPD grade IV according to the GOLD classification,\n  * Some GOLD III COPD and any patient with a respiratory defect defined as: oxygen dependence and \u002F or FEV1 \\\u003C40% normal and \u002F or, DLCO \\\u003C40% predictive value and \u002F or vital capacity \\\u003C40% predictive value,\n* Contraindication to acetazolamide: hypersensitivity to acetazolamide, severe hepatic, renal or adrenal insufficiency, sulfonamide intolerance, history of renal colic, allergy to wheat other than celiac disease,\n* Patient currently receiving one or more treatments described in section 6.9 of the protocol,\n* History of cancer, with the exception of cancers in complete remission for more than 5 years, completely resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer,\n* People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code, including: person deprived of freedom by an administrative or judicial decision, adult being the object of a legal protection measure or outside a state to express their consent, pregnant or breastfeeding women",{"count":157,"type":20},27,"INTERVENTIONAL",[160],"PHASE1","The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to:\n\n1. The over-expression of carbonic anhydrases in this type of cancer,\n2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines,\n3. The observed synergy between irradiation and inhibition of carbonic anhydrases,\n4. Potential anti-tumor immune effect caused by decreased extracellular acidity.",[163],"Small Cell Lung Cancer",[165],"acetazolamide","2026-01-16",{"date":168,"type":29},"2026-01-20",{"date":170,"type":29},"2019-08-02",{"date":172,"type":20},"2027-04-27",{"name":174,"class":62},"Centre Antoine Lacassagne",2,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":158,"phases":186,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":63},"100499405","perioperative-stress-management-in-outpatient-surgery-with-l-tyrosine-supplementation-spot-100499405","NCT05782829","Perioperative Stress Management in Outpatient Surgery With L-tyrosine Supplementation (SPOT)","Perioperative Stress Management in Outpatient Surgery With L-tyrosine Supplementation","SPOT","Inclusion Criteria:\n\n* Membership of a social security scheme or equivalent\n* At least 18 years of age\n* Able to express consent\n* Indication of unilateral or bilateral inguinal hernia cure\n* General anaesthesia proposed and retained for inguinal hernia treatment regardless of surgical technique\n\nExclusion Criteria:\n\n* Surgical indication for another reason or hernial cure associated with another procedure\n* Smoking estimated at more than 35 pack-years\n* History of psychiatric pathology\n* ASA 3 or 4 according to the American Society of Anesthesiologists classification. As a reminder, an ASA 3 class concerns a patient with a severe but not disabling general disease, and an ASA 4 class concerns a patient with a disabling general disease involving the vital prognosis.\n* ASA 2 and having at least one of the following pathologies or patients treated with -blockers: insulin-dependent diabetes, high blood pressure, heart rhythm disorder, dysthyroidism, progressive neurological disease, long-term benzodiazepines.\n* Starch allergy or intolerance","75 Years",{"count":100,"type":20},[187],"NA","Patient undergoing surgery is exposed to many stressors: diachronic (gesture anticipation), synchronic (intraoperative aggression) and historical (subject's personality). Reducing the level of stress experienced is a factor for improving the quality of the surgical gesture and the simplicity of the follow-up. The previous methods used were intended to reduce the body's reactivity to aggressions through anaesthesia consultation and L-Tyrosine supplementation. Currently with the progression of outpatient surgery and the need for early rehabilitation, L-Tyrosine supplementation is suppressed to improve recovery. Some patients, however, have a high level of stress that may require anxiolysis when the ideal treatment does not exist (ineffective hydroxyzine, benzodiazepines having many side effects). The strategy of this work is to improve the body's ability to respond to stressors, by administering l-tyrosine with no impact on waking or returning home.",[190],"Stress",[192,193],"L-Tyrosine supplementation","Perioperative stress","2025-12-02",{"date":196,"type":29},"2025-12-08",{"date":198,"type":29},"2023-11-14",{"date":200,"type":20},"2026-05",{"name":202,"class":62},"Centre Hospitalier Universitaire de Nice",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":210,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":158,"phases":213,"briefSummary":214,"conditions":215,"keywords":221,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":63},"100576488","tdcs-effect-on-psychotic-symptoms-in-dementia-with-lewy-bodies-dlb-and-impacts-on-caregiver-burden-100576488","NCT06785948","tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden","MCL-tDCS","Inclusion Criteria:\n\n* Male or Female, aged over 60,\n* Diagnosed with a neurodegenerative pathology of the DLB type, at a moderate stage, according to the McKeith and al. (2017) criteria\n* No change in antiparkinsonian or psychotropic medications, or cholinesterase inhibitors, for a period of one month prior to inclusion,\n* Mini Mental State Examination (MMSE) \\> 15,\n* Composite score called \"psychotic factor\" (corresponding to the sum of the psychotic-type symptoms sub-scores from the NPI \\[12\\]) greater than 0,\n* Presence of a family caregiver,\n* Sufficient written and oral expression in French,\n* Written informed consent signed by the patient and his\u002Fher family caregiver\n\nExclusion Criteria:\n\n* History of alcoholism, drug addiction or neurological diseases such as brain trauma, epilepsy, encephalitis, intracranial normal-pressure hydrocephalus, etc. which may lead to cognitive impairment,\n* Concomitant major psychiatric illness,\n* Significant physical illness or comorbidities\n* History of moderate to severe visual impairment secondary to glaucoma, cataract or macular degeneration,\n* Patient under guardianship or curators","60 Years",{"count":212,"type":20},30,[187],"The goal of this pilot prospective study is to evaluate the effect of tDCS on psychotic-like symptoms in patients with Lewy Body Dementia (LBD). The main questions it aims to answer are:\n\n* What is the effect of tDCS on neuropsychiatric symptoms, especially psychotic-like symptoms?\n* What is the impact of tDCS on caregiver burden?\n\nResearchers will compare active tDCS (2mA stimulation, anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital) to Sham tDCS (placebo stimulation, no intensity applied) to see if there is an effect on reducing psychotic-like symptoms and on caregiver burden.\n\nParticipants will:\n\n* Undergo a stimulation phase consisting of 10 tDCS sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).\n* perform assessments at T0 (inclusion), T1 (at the end of the stimulation phase), and T2 (follow-up at 8 weeks post stimulation).",[216,217,218,219,220],"Lewy Body Dementia","Lewy Body Dementia With Behavioral Disturbance","Burden, Caregiver","Lewy Body Disease","Dementia With Lewy Bodies",[222,223,224,225],"Transcranial Direct-Current Stimulation (t-DCS)","Brain stimulation","Psychotic symptoms","Caregiver burden","2025-09-30",{"date":228,"type":29},"2025-10-01",{"date":230,"type":29},"2025-01-10",{"date":59,"type":20},{"name":233,"class":62},"Association de Recherche Bibliographique pour les Neurosciences",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":158,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":63},"100418633","video-oculography-and-parkinsons-disease-100418633","NCT04731246","Video-oculography and Parkinson's Disease","Video-oculography and Parkinson's Disease: A Prospective Study","\\*Inclusion Criteria:\n\n1. Male or Female;\n2. Clinically defined idiopathic Parkinson's Disease (PD);\n3. Brain MRI performed in routine care in the 12 months preceding inclusion;\n4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;\n5. Hoehn \\& Yahr score: 1 to 3;\n6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);\n7. Neuro-cognitive disorders: absent or minor (according to DSM5);\n8. Sufficient written and oral expression in French;\n9. Covered by a health insurance system;\n10. Written informed consent signed by the patient;\n11. Presence of a caregiver.\n\n    \\* Exclusion Criteria:\n12. Psychiatric comorbidity (except anxiety or mild to moderate depression);\n13. Neurological comorbidity, if significant;\n14. Brain MRI showing:\n\n    1. significant cerebrovascular pathology (Fazekas I admitted),\n    2. another brain disease, including stroke.\n15. Major cognitive impairment;\n16. Absolute exclusion criteria and \"Red flags\" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system:\n\n    * Cerebellar syndrome\n    * Vertical oculomotricity disorders on clinical examination\n    * Motor symptoms restricted to the lower limbs\n    * Bilateral and perfectly symmetrical parkinsonism\n    * Early dystonia\n    * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)\n    * Progressive aphasia or apraxia\n    * Moderate or severe postural instability and \u002F or early falls\n    * Early bulbar dysfunction (dysarthria, swallowing disorders)\n    * Ventilatory dysfunction (inspiration)\n    * Severe dysautonomia\n    * DOPA-resistance\n    * Neuroleptic treatment or related\n17. Normal MIBG myocardial scintigraphy (if performed).",{"count":212,"type":20},[187],"This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):\n\n* the evolution of oculomotricity markers over time.\n* the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years.\n* the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography.\n* the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.",[245],"Parkinson Disease, Idiopathic",[247,248,249,250,251,252,253,254],"Parkinson's disease","Video-oculography","Oculomotor disorders","Oculomotricity","Neuropsychological evaluations","Movement disorder","Motor disorders","Non-motor fluctuations",{"date":228,"type":29},{"date":257,"type":29},"2021-07-07",{"date":259,"type":20},"2032-01",{"name":233,"class":62},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":158,"phases":271,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100472177","phase-3-efficacy-of-a-sequential-treatment-strategy-in-rheumatoid-arthritis-100472177","NCT05428488","Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis. A Randomized Controlled Trial With an Independent Efficacy Assessor.","SEQUENS-RA","Inclusion Criteria:\n\n* Aged between 18 or above\n* Rheumatoid arthritis according to ACR-EULAR 2010 (American College of Rheumatology-European League Against Rheumatism)\n* ACPA positive\n* Under methotrexate or leflunomide treatment for at least 3 months\n* DAS28-CRP\\>3.2 under methotrexate or leflunomide calculated with CRP dated less than 7 days from baseline\n* Escape under synthetic background treatment defined by an elevation of C-reactive protein (CRP) (CRP\\> 5mg\u002FL ) or Erythrocyte sedimentation rate (ESR) (for men: \\> age in years\u002F2 ; for women: \\> age (+10) \u002F2)) within the last 6 months before baseline\n* Targeted DMARDs (biological and targeted synthetic DMARDs) naïve\n* Indication for a TNF inhibitor\n\nExclusion Criteria:\n\n* Subject unable to read or\u002Fand write\n* Planned longer stay outside the region that prevents compliance with the visit plan\n* Subject unable to sign informed consent form\n* Subject not covered by public health insurance\n* Dementia\n* Fibromyalgia\n* Contra-indications to TNF inhibitor and\u002For Abatacept\n* Absence of tuberculosis screening in the previous 3 months before baseline\n* Patient with untreated active tuberculosis\n* Patient who cannot be followed during 48 weeks\n* Drug addiction, addiction to alcohol\n* Protected populations according to the French Public Health Code Articles L1121-5,6,8 (For example, pregnant, parturient or lactating women, prisoners, adults under guardianship or otherwise unable to consent).\n* Women of child bearing potential, unless they are using an effective method of birth control\n* Patient under law protection\n* Prisoners\n* Subject who are in a dependency or employment with the sponsor or the investigator\n* Participation in another interventional clinical trial or administration of an investigational product within the last 4 weeks before the screening date\n* Subject with moderate to severe heart failure (class 3 or class 4 cardiac disease as defined by the New York Heart Association Functional Classification)\n* Patients had a history of chronic obstructive pulmonary disease (COPD) and heavy smoking\n* Patients had a planned surgical procedure at least 30 days before the screening day\n* Known allergy or intolerance to an anti-TNF therapy\n* Hypersensitivity to the Abatacept or to any of its excipients\n* Patient with untreated active hepatitis B\n* Patient vaccinated with a live vaccine within 30 days prior to screening\n* Patients with an Inflammatory Bowel Disease (IBD) (loss of chance if switching from an anti-TNF to abatacept)",{"count":270,"type":20},220,[272],"PHASE3","In rheumatoid arthritis (RA), the consensual 1st line conventional synthetic disease modifying antirheumatic drugs (csDMARD) of RA is methotrexate (MTX). In case of contra-indication or intolerance to MTX, leflunomide is an alternative. If the treatment target is not achieved with csDMARD strategy, addition of a biological DMARD (TNF inhibitors, anti-Interleukin 6 (anti-IL6)), abatacept, or rituximab) or a targeted synthetic (ts) DMARD (JAK inhibitors) is considered.\n\nCurrent practice is to start a bDMARD (biologic Disease Modifying Antirheumatic Drugs) and especially TNF inhibitors (etanercept or monoclonal anti-TNF antibodies) with the benefit of hindsight. However, abatacept and TNF inhibitors have demonstrated similar efficacy in patients with insufficient response to csDMARD (AMPLE trial).\n\nAlthough abatacept has shown a very good tolerance profile that might be superior to other bDMARDs rheumatologists might be reluctant to use it as a first line bDMARD as there is a belief of a slower efficacy compared to other bDMARDs or JAK inhibitors. Indeed, in real world study, compared to TNF inhibitors it seems that discontinuation of abatacept is more related to lack of effectiveness than safety issues.\n\nInvestigators have hypothesized that first rapidly controlling the inflammation phase, using TNF inhibitors followed by abatacept to induce an immunological remission would optimize response and tolerance of ACPA positive patients with RA. To demonstrate our hypothesis, the investigaors propose a randomized controlled trial with one arm receiving an induction therapy for 12 weeks with a TNF inhibitor followed by a cell-targeted bDMARD (abatacept) and the other arm, receiving TNF inhibitors.",[275],"Rheumatoid Arthritis",[277,278,279,280,281],"Rheumatoid arthritis","sequential therapeutic strategy","immunological remission","anti-TNF","abatacept","2025-09-29",{"date":284,"type":29},"2025-10-03",{"date":286,"type":29},"2022-11-28",{"date":288,"type":20},"2027-11",{"name":290,"class":62},"University Hospital, Montpellier",17,{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":158,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":309,"leadSponsor":311,"locationsCount":175},"100582439","impact-of-individual-radiosensitivity-on-late-toxicities-of-radiosurgery-in-essential-trigeminal-neuralgia-100582439","NCT06863324","Impact of Individual Radiosensitivity on Late Toxicities of Radiosurgery in Essential Trigeminal Neuralgia","TRITON","Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* Patients treated for trigeminal neuralgia by radiosurgery at CHPG more than 12 months ago\n* Treatment of the nerve with a 4 or 5 mm cone\n* Patient affiliated to social security\n* Patient agreement: obtaining the patient's non-opposition (France) or consent (Monaco)\n\nExclusion Criteria:\n\n* Patients pre-treated for neuralgia by another invasive method: thermo coagulation, decompression surgery, radiosurgery...\n* Patients with multiple sclerosis (MS)\n* Secondary neuralgia\n* Hypoesthesia pre-existing treatment\n* Protected persons: persons deprived of their liberty, patients under guardianship or trusteeship",{"count":300,"type":20},74,[187],"Trigeminal neuralgia is intense, electric-shock-like facial pain, most often triggered by touch, chewing or speech. It results from dysfunction of the trigeminal nerve, the 5th cranial nerve. In most cases, no cause is found, and trigeminal neuralgia is termed \"essential\". In the first instance, treatment is based on medication. In cases of drug resistance, radiosurgery is a possible treatment option. This involves performing neurolysis, delivering a very high dose of ionizing radiation to the trigeminal nerve. The immediate success rate of radiosurgery is 80-90%.\n\nHowever, in the long term, around 30% of patients experience complications (mainly hypoesthesia of the face on the treated side, paresthesias, masticatory disorders, neuropathic pain) and 30% of patients experience a recurrence of neuralgic pain. Most of these complications are permanent, and there are very few effective treatments, either medical or physical. Recurrence and complications are correlated, i.e. patients with hypoesthesia have a lower risk of recurrence. Certain technical parameters are associated with the efficacy and toxicity of radiosurgery, notably the position of the point of impact of the rays on the nerve. However, for identical treatment techniques, there are currently no known prognostic criteria for the efficacy and toxicity of radiosurgery.\n\nNumerous radiobiological studies have demonstrated that sensitivity to ionizing radiation differs from one individual to another, with each person having his or her own tolerance threshold. Indeed, 5-10% of patients are hypersensitive to ionizing radiation and are at very high risk of developing late complications \\[Bentzen et al. 2010\\]. There are currently commercial tests for individual radiosensitivity, based on a simple blood test, whose clinical value has been demonstrated in predicting complications in patients irradiated for breast or prostate cancer. These tests are based on the rate of radiation-induced lymphocyte apoptosis, known as the RILA (Radiation Induced Lymphocyte Apoptosis) score. Numerous teams have shown retrospectively and then prospectively that a high RILA score is significantly correlated with the absence of the development of radiation-induced late adverse events, with a negative predictive value of over 90% (level of evidence 1) \\[Azria et al. 2015; Mirjolet et al. 2016; Talbot et al. 2019\\]. In practical terms, the test gives a lymphocyte apoptosis score for each patient. A cut-off point is set below which the patient is considered \"radiation hypersensitive\".\n\nIn this study, the investigators propose to correlate the RILA score with the occurrence of severe late toxicity in patients treated by radiosurgery for trigeminal neuralgia.\n\nIn the event of a positive result, this would make it possible either to adapt the radiosurgery technique to minimize the risk of late complications, or to contraindicate radiosurgery and refer patients to other treatment methods.",[304],"Trigeminal Neuralgia Treated by Radiosurgery","2025-04-01",{"date":307,"type":29},"2025-04-02",{"date":305,"type":29},{"date":310,"type":20},"2028-03",{"name":202,"class":62},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":332},"100148938","characterization-of-the-mechanisms-of-resistance-to-azacitidine-100148938","NCT01210274","Characterization of the Mechanisms of Resistance to Azacitidine","Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia","Inclusion Criteria:\n\n* Age ≥ 18 years\n* High Risk or Intermediate 2 MDS (IPSS)\n* AML-MD (WHO classification)\n* Treatment with minimum three to six cycles of Azacitidine\n* Informed consent form signed\n\nExclusion Criteria:\n\n* Treatment with others chemotherapies alone or in association",{"count":320,"type":20},250,"Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has been mainly achieved through a rigorous empirical and clinical research, but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized. The primary mode of action of Azacytidine is through DNA demethylation, and integration in to mRNA that favor traduction inhibition. The impact of this molecule on various cell death programs involved in the elimination of leukemic cells : apoptosis and autophagy is currently poorly known.\n\nThe research program and clinical studies we proposed focus on two major aspects:\n\n\\- Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of apoptosis versus autophagy.\n\n\\- Secondary Objective: Reversion of Azacytidine resistance using different drugs targeting apoptosis and\u002For autophagy. Our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).",[323],"Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia","2025-03-17",{"date":326,"type":29},"2025-03-19",{"date":328,"type":4},"2010-09",{"date":330,"type":20},"2025-09",{"name":202,"class":62},4,{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":5},"100507295","glial-fibrillary-acidic-protein-gfap-and-ubiquitin-carboxy-terminal-hydrolase-l1-uch-l1-to-exclude-lesions-linked-to-significant-traumatic-brain-injuries-100507295","NCT05885529","Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries","Added Value, Performance and Acceptance of the \"GFAP-UCH-L1\" Pair in the Evaluation of Subjects with Mild Traumatic Brain Injury (MTBI) At Intermediate Risk of Complications","GUEST","Inclusion Criteria:\n\n* Traumatic brain injury defined by\n\n  * Impact on the skull or the face AND OR\n  * Acceleration \u002F deceleration\n* Glasgow Coma Scal 13, 14 or 15\n* One of the following 4 criteria:\n\n  * \\> 65 years treated with anti-platelet agent,\n  * GCS \\\u003C 15 two hours after the trauma if associated intoxication (alcohol, narcotic, psychotropic),\n  * Trauma with high kinetics (for information only: a risk mechanism (pedestrian knocked down by a motorized vehicle, ejection from a vehicle, fall from more than 3 steps (more than one meter), etc.),\n  * Amnesia of facts \\> 30 min before the trauma.\n* Having a blood sample taken as part of care with a delay between the clinical event and the biological sample \\\u003C 12 hours\n* Having a CT-scan prescription as part of the MTBI evaluation\n* Patient who signed an informed consent form\n\nExclusion Criteria:\n\n* Person not affiliated or not benefiting from a health insurance scheme.\n* Person under judicial protection.\n* Person with restrictions of freedom or subject to Articles L.3212-1 and L.3213-1, and not included in Article L.1122-8 of the French CSP\n* Blood collection time \\> 12 hours\n* Subjects for which a scan would be carried out systematically, including:\n\n  * GCS \\\u003C13 (moderate or severe trauma),\n  * congenital hemostasis disorders or patient on anti-coagulant treatment,\n  * clinical signs evoking a fracture of the vault or the base of the skull,\n  * more than one episode of vomiting,\n  * post-traumatic convulsion,\n  * focal neurological deficit.\n* Obstacle to follow-up at D7\n* Malignant melanomas",{"count":342,"type":20},1500,"The goal of this observational study is to evaluate the performance of UCH-L1 and GFAP combined in patients with a mild traumatic brain injury. The main question :\n\n• Does the combination of UCH-L1 and GFAP can exclude brain injuries detected with CT scan in the first twelve hours after a mild traumatic brain injury?\n\nParticipants will do the exams planed in routine care and :\n\n* during the expected blood sampling an additional blood sample will be done,\n* seven days after the discharge a call will be done by the investigator.",[345],"Traumatic Brain Injury",[347,348,349],"UCHL1","GFAP","CT scan","2025-02-17",{"date":352,"type":29},"2025-02-19",{"date":354,"type":29},"2024-04-19",{"date":356,"type":20},"2026-03-30",{"name":61,"class":62},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":365,"targetDuration":366,"studyType":21,"phases":4,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":63},"100491293","observational-study-on-the-treatment-of-trigeminal-neuralgia-by-radiosurgery-100491293","NCT05677243","Observational Study on the Treatment of Trigeminal Neuralgia by Radiosurgery","NATURE","Inclusion Criteria:\n\n* Classical trigeminal neuralgia according the International Classification of Headache Disorders\n* Trigeminal neuralgia resistant to the maximum tolerated medical therapy, with pain intensity according to the Barrow Neurological Institute (BNI) score IV or V.\n* Patients aged \\> 18\n\nExclusion Criteria:\n\n* Patients suffering from secondary Trigeminal neuralgia (tumour in the cerebellopontine angle, arteriovenous malformation or multiple sclerosis)\n* Previous history of radiosurgery procedure",{"count":100,"type":20},"10 Years","This study aims to evaluate the outcome of patient treated by radiosurgery on LINAC with high dose rate for classical trigeminal neuralgia",[369],"Trigeminal Neuralgia",[369,371,372,373,374],"Radiosurgery","LINAC","Pain relief","Hypesthesia",{"date":352,"type":29},{"date":377,"type":29},"2021-12-15",{"date":379,"type":20},"2036-12",{"name":61,"class":62},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":388,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":158,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":407},"100433236","evaluation-of-electrocardiographic-measurements-by-high-density-electrode-ecg-100433236","NCT04921501","Evaluation of Electrocardiographic Measurements by High Density Electrode ECG","ECG-HD","Inclusion Criteria:\n\n* Patient managed at the Bordeaux University Hospital for assessment of documented severe ventricular arrhythmia (VF, sudden resuscitated death) or suspected (syncope, family history of sudden death, ECG or Holter abnormality) or impaired ventricular conduction, OR\n* Patients managed for prophylactic ventricular defibrillator implantation, according to international recommendations: Heart disease with ejection fraction \\\u003C 35%, heart disease with sustained ventricular tachycardia, cardiomyopathies with high rhythmic risk,\n* Women of childbearing age with effective contraception.\n\nExclusion Criteria:\n\n* patients under 14 years old,\n* pregnant or nursing woman.","14 Years",{"count":390,"type":20},1800,[187],"Cardiac electrical activity is detected on the body surface with conventional electrocardiography involving 12 leads (ECG 12). A limitation of the current ECG technique is that recordings are obtained from only 6 independent precordial leads pairs ; which may miss cardiac potentials from spatially limited regions. More extensive sampling of the body surface may contribute to additional clinical information. The present study investigates the additional sensitivity of ECG using 128 body surface leads (High Density (HD) ECG) in measuring global or regional cardiac activity.",[394],"Ventricular Arrhythmias",[396,397],"Signal Averaging ECG","Cardiac electrophysiology","2024-12-19",{"date":400,"type":29},"2024-12-24",{"date":402,"type":29},"2021-04-06",{"date":404,"type":20},"2027-04",{"name":406,"class":62},"University Hospital, Bordeaux",11,""]